The role of AI in therapeutic research

The role of artificial intelligence (AI) in therapeutic research has become increasingly prominent in recent years, with the potential to revolutionize drug discovery, testing, and personalized medicine. This transformative technology is poised to reshape the future of healthcare, offering unprecedented opportunities for the development of novel treatments and therapies tailored to individual patients’ needs.

One of the most significant applications of AI in therapeutic research is in the realm of drug discovery. Traditionally, the process of identifying and developing new drugs has been time-consuming, labor-intensive, and costly, with a high rate of failure. However, AI-driven algorithms and machine learning techniques have the potential to streamline this process, enabling researchers to analyze vast amounts of data and identify promising drug candidates more quickly and efficiently than ever before.

For instance, AI can be used to mine large databases of chemical compounds, identifying those with the potential to interact with specific biological targets and predicting their likely effects on the human body. This can help researchers to narrow down the field of potential drug candidates, reducing the time and resources required for subsequent testing and development. Additionally, AI-driven simulations can help to predict how drugs will behave in the human body, enabling researchers to optimize their chemical structures and improve their efficacy and safety profiles.

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model. 

Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
X
LinkedIn
Poolbeg Pharma

More articles like this

GLP-1 receptor agonists transform diabetes treatment

GLP-1 (glucagon-like peptide-1) and its receptor agonists (GLP-1RAs) have emerged as a groundbreaking class of drugs in diabetes management, particularly due to their impressive efficacy in reducing obesity, a key factor in type 2 diabetes. Jeremy

AI revolutionising the pharmaceutical industry

The rapid advancement of artificial intelligence (AI) is making significant strides in the pharmaceutical sector. Since its inception, this industry has embraced AI and machine learning, continuing its legacy of innovation. The integration of these technologies

Poolbeg Pharma publishes Annual Report and AGM Notice

Poolbeg Pharma plc (LON: POLB, OTCQB: POLBF), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, has confirmed that the Company’s Annual Report and Accounts for the period ended

Poolbeg Pharma expands treatment into new markets

Poolbeg Pharma said it had made progress last year in expanding its treatments into new markets, with significant pipeline advancements and strategic deals. The company said it had made a strategic expansion into the treatment of

Poolbeg Pharma granted significant POLB 001 patent in United States

Poolbeg Pharma plc (LON:POLB, OTCQB:POLBF), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, has announced that, further to its announcement on 20 March 2024, the Company has received the fully granted

AI impact on biopharma business models

The culture of collaboration in the Pacific Northwest, the impact of AI on biopharma, and the shape of new business models driven by AI were all topics at a panel discussion Wednesday in Seattle at the

POLB 001: Targeting CRS in Cancer Immunotherapy

Phase 2 Ready orally administered p38 MAP Kinase inhibitor – a preventative therapy targeting an addressable market of more than $10 billion. POLB 001 aims to target the Cytokine Release Syndrome (CRS) associated with many cancer